Evaluating Community-Based Intrathecal Baclofen Therapy: Effectiveness, Safety, and Feasibility

Simone M.E. van der Gaag*, Sander P.G. Frankema, Eva S. van der Ploeg, Sara J. Baart, Frank J.M.P. Huygen

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

9 Downloads (Pure)



Intrathecal baclofen (ITB) is used for the treatment of intractable spasticity. The burden of traveling for ITB screening and aftercare is problematic for nursing home residents with severe spasticity and seems to result in undertreatment of spasticity. The aim of this study is to evaluate the effectiveness, safety, and feasibility of ITB for nursing home residents treated in their home, describing the selection phase, the initial trial of ITB, and aftercare up to 3 months after implantation of an ITB pump. 


This retrospective database study included immobile, adult nursing home residents with severe spasticity, referred to an Ambulatory Care Clinic between 2016 and 2021. When eligible, an ITB trial was performed by ITB experts in the nursing home. If a permanent pump was implanted, dose titration and aftercare were performed on location. 


A total of 102 patients were referred; 80 underwent an ITB trial on location, and 94% improved significantly on the Modified Ashworth Scale and clonus scale pre-ITB trial versus post-ITB trial, as well as at 3 months post-implantation. There was a low incidence of adverse events, mostly procedure- and drug-related. 


This study indicates that selection, testing, and aftercare for ITB on location is effective and safe.

Original languageEnglish
Article number1840
JournalJournal of Clinical Medicine
Issue number7
Publication statusPublished - Apr 2024

Bibliographical note

Publisher Copyright:
© 2024 by the authors.


Dive into the research topics of 'Evaluating Community-Based Intrathecal Baclofen Therapy: Effectiveness, Safety, and Feasibility'. Together they form a unique fingerprint.

Cite this